Immunohistochemical and molecular genetic analysis of a case of T-cell-rich B-cell lymphoma presenting in bone marrow

2008 ◽  
Vol 15 (3) ◽  
pp. 211-217
Author(s):  
A.B. PROVAN ◽  
B. WILKINS ◽  
E. HODGES ◽  
R.D. HYDE ◽  
J.L. SMITH
2021 ◽  
pp. 104063872110110
Author(s):  
Alessandro Ferrari ◽  
Marzia Cozzi ◽  
Luca Aresu ◽  
Valeria Martini

An 8-y-old spayed female Beagle dog was presented with peripheral lymphadenomegaly. Lymph node cytology and flow cytometry led to the diagnosis of large B-cell lymphoma (LBCL). We detected minimal percentages of LBCL cells in peripheral blood and bone marrow samples. However, a monomorphic population of neoplastic cells different from those found in the lymph node was found in the bone marrow. T-cell acute lymphoblastic leukemia was suspected based on flow cytometric immunophenotyping. PCR for antigen receptor rearrangement (PARR) revealed clonal rearrangement of both B-cell and T-cell receptors, and the presence of both neoplastic clones in the lymph node, peripheral blood, and bone marrow. The dog was treated with multi-agent chemotherapy but died 46 d following diagnosis. Tumor staging and patient classification are needed to accurately establish a prognosis and select the most appropriate therapeutic protocol.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5299-5299
Author(s):  
Yonghong Zhang ◽  
Ling Jin ◽  
Jing Yang ◽  
Yanlong Duan ◽  
Chunjv Zhou ◽  
...  

Abstract One hundred and nineteen children with non-Hodgkin lymphoma were treated between February 2003 and December 2006 in Beijing Children’s Hospital on BCH-2003-NHL protocol. The diagnosis was made by histopathology of the biopsied tissue and/or bone marrow, and disease was classified according to WHO-2001 pathologic classification. We applied modified LMB89 protocol to cases with B-cell lymphoma; modified BFM90-ALL protocol for lymphoblastic lymphoma and cutaneous T-cell/NK cell lymphoma; and modified BFM90-ALCL protocol for anaplastic large-cell lymphoma (ALCL). There were 50 cases (42%) of B cell lymphoma including 32 cases of Burkitt¡’s lymphoma, 10 cases of Burkitt-like lymphoma and 8 cases of diffuse large B cell lymphoma; 44 cases (37%) of lymphoblastic lymphoma; 19 cases (16%) of ALCL; and 6 cases (5%) of cutaneous T-cell/NK cell lymphoma. The 85 boys and 34 girls (ratio, 2.5:1) ranged in age from 2 to 15 years (median, 7.8 years) at diagnosis. B cell lymphoma typically presented as abdomen mass and acute abdomen; nasopharynx and tonsil were also common sites of involvement. Lymphoblastic lymphoma generally presented with mediastinal mass and bone marrow involvement. There was no typical presentation for ALCL. According to the St. Jude staging system, 19 cases had stage I–II, and 94 cases stage III–VI diseases (exclude 6 cases of cutaneous T-cell/NK cell lymphoma). Seven cases had CNS involvement and 25 cases involved bone marrow. The treatment duration was 2 to 8 months for B-cell lymphoma, 2.5 to 3 years for lymphoblastic lymphoma and 1 to 1.5 years for ALCL. The follow-up rate was 100% and median observation period was 23 months. The overall survival (OS) at 3 years was 90.7% and the 3-year event-free survival (EFS) estimate was 82.3%. For B-cell lymphoma, 3-year OS was 88.68% and 3-year EFS was 81.8%. For lymphoblastoma lymphoma, the rates were 89.3% and 69.4%, respectively. All cases of ALCL are alive with on undergoing treatment for relapse. Patients with ALCL achieved the best 3-year OS (100%) and had 3-year EFS of 94.2%. Grade 3 or 4 bone marrow suppression occurred in 97.5% of patients with B-cell lymphoma, 100% of those with lymphoblastic lymphoma and 89.5% of cases with ALCL. As of to date, 11 patients have died, the causes of death include infection (n=4), abandonment of therapy (n=6) and relapse (n=1). Univarate analysis showed that stage IV disease, failure to achieve complete remission after 3 months of treatment, and bulky mass are were associated with poor prognosis £all P values <0.05£©. In summary, we have achieved excellent treatment results using modified international protocols. Infection and financial problem remained the main reasons of treatment failure.


2005 ◽  
Vol 46 (3) ◽  
pp. 465-469 ◽  
Author(s):  
Bülent ÖzgÖnenel ◽  
Süreyya Savaşan ◽  
Raja Rabah ◽  
Anwar Mohamed ◽  
Barbara Cushing

2020 ◽  
Vol 154 (4) ◽  
pp. 428-449
Author(s):  
Sarah E Gibson ◽  
Steven H Swerdlow

Abstract Objectives Primary cutaneous marginal zone lymphoma (PCMZL) is 1 of the 3 major subtypes of primary cutaneous B-cell lymphoma. The diagnosis of PCMZL may be challenging, as the differential diagnosis includes benign cutaneous lymphoproliferations as well as other primary or secondary cutaneous B-cell or T-cell lymphomas. This review describes our approach to the diagnosis of PCMZL. Methods Two cases are presented that illustrate how we diagnose each of the 2 subtypes of PCMZL. The clinicopathologic features of PCMZL and the ways in which these cases can be distinguished from both benign and other neoplastic entities are emphasized. Results A definitive diagnosis of PCMZL requires the incorporation of histologic and immunophenotypic features, molecular genetic studies in some cases, and just as importantly, clinical findings. Emerging data suggest that the heavy chain class-switched cases may be more like a clonal chronic lymphoproliferative disorder. Conclusions The 2 subtypes of PCMZL create different diagnostic challenges and require the use of a multiparameter approach. Although very indolent, it is important to distinguish PCMZLs from reactive proliferations, because they frequently recur and may require antineoplastic therapies. It is also critical to distinguish PCMZLs from other B- or T-cell lymphomas so that patients are properly evaluated and not overtreated.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5273-5273
Author(s):  
Marina Motta ◽  
Chiara Bottelli ◽  
Chiara Cattaneo ◽  
Giovanna Tabellini ◽  
Silvia Parolini ◽  
...  

Abstract Background Hemophagocytic Lymphohystiocytosis (HLH) is a rare disorder, characterized by uncontrolled hyperinflammation, fever, cytopenias, hepatosplenomegaly and hemophagocytosis caused by genetic defects, e.g. perforin 1, causing impaired natural killer (NK) and cytotoxic T-cell function. A disease characterized by hyperactive phagocytosis similar to familial HLH can occasionally develop in adult patients (pts) and is called acquired hemophagocytic syndrome (AHS). The diagnosis of AHS is often overlooked because of its rarity and heterogeneous clinical presentation. It is usually associated with virus infection (VAHS), autoimmune disorders or malignancies. AHS has been described in Asian pts with lymphoma particularly of T-cell or intravascular large B cell phenotype but has been only occasionally reported in pts of Western origin. Aims To evaluate the occurrence of AHS in adult lymphoma pts of Western origin, focusing on its biological and clinical features. Methods From 2/03 through 02/08 the revised diagnostic criteria of the Histiocyte Society were applied to lymphoma pts presenting with persistent FUO, unexplained cytopenia or clinical signs of AHS. Work-up included detection of HHV-8, EBV, CMV, Parvovirus viral DNA, evaluation of NK activity of PBMCs by 4-hour51Cr-release assay with K562 cells, perforin expression on NK cells by flow cytometry, and by immunohystochemistry on bone marrow biopsy and analysis of perforin gene mutations by PCR and sequencing. Results Fifteen pts fulfilling the criteria for HLH were identified. Their M/F ratio was 1,5 and median age was 66 (31–79). Lymphoma diagnoses clustered in three groups: 5 cases of indolent B cell lymphoma (4 SLL/CLL, 1 SMZL), 5 cases of diffuse large B cell lymphoma (DLBCL), two of which associated with Hodgkin lymphoma (HL),1 case of HL, and 4 cases of T cell lymphoma (1 anaplastic, 1 peripheral unspecified and 2 enteropathic). Among HLH diagnostic criteria, fever, cytopenia and high ferritin occurred in 100%, hypertriglyceridemia in 86%; hypofibrinogenemia and splenomegaly in 66%, and prominent bone marrow hemophagocytosis in 46% of cases. Median Hgb level was 9,1 g/L, ANC 0,7 × 109/L and platelets 23 × 109/L. Median trygliceride levels was 305 mg/dL, fibrinogen 122 mg/dL ferritin 6800 ng/mL. Moreover LDH was elevated in 13/15 cases (median 711 U/L). No significant differences were recorded between the different types of lymphoma except for a lower platelet count in pts with indolent B cell lymphoma (P=.008). No recurrent immunological abnormalities were identified except for direct antiglobulin test positivity in 5/8 pts with B cell lymphoma, without signs of overt hemolysis. Viral DNA was detected only in 3 pts (1 EBV, 1 CMV and 1 CMV+EBV). Biological investigations showed defective NK activity in 83% of pts. Among 9 evaluable pts, analysis of PRF1 gene identified G1070A mutation in 1 pt. and A91V heterozygous polymorphism in 2 pts showing defective PRF1 expression of NK cells by flow cytometry. Perforin expression on bone marrow biopsies was increased in 6 of 11 evaluable pts. Twelve pts died 1–120 days after diagnosis in spite of therapy with steroid, rituximab, high-dose IgG, antivirals and etoposide. Three are alive 22–34+ months after diagnosis. They had not distinctive clinicopathological features at presentation. Conclusions AHS is not unusual in Western adults with lymphoma of T-cell but also of B cell phenotype, being overrepresented in SLL/CLL and in DLBCL, particularly when associated with HL. Genetic abnormalities of PRF1 are predisposing factors in some cases. However further mechanisms of defective NK function likely account for the development of this very severe condition and should be actively explored in order to ameliorate its dismal prognosis.


2018 ◽  
Vol 10 (01) ◽  
pp. 017-020
Author(s):  
Sadia Sultan ◽  
Naseer Baloch ◽  
Zeeshan Ansar Ahmed ◽  
Syed Mohammed Irfan ◽  
Saira Parveen

Abstract BACKGROUND: Limited information is available from developing countries in patients of non-Hodgkin's lymphoma (NHL). Hence, we reviewed the demographical profile along with bone marrow infiltration pattern in patients with NHL presented at Liaquat National Hospital and Medical College. MATERIALS AND METHODS: In this descriptive study, adult patients with NHL were enrolled from January 2011 to December 2015. RESULTS: One hundred and Eighty-four histopathologically confirmed cases of NHL were identified. There were 139 males and 45 females, with a male-to-female ratio of 3:1. The mean age was 48.5 ± 16.0 years with the median age of 50 years. B-symptoms were present in 80.4% of patients. Lymph node enlargement was present in 71.1% of the cases. One hundred and sixty-eight patients had B-cell lymphoma (91.3%) and 16 patients had T-cell lymphoma (8.6%). Overall 158 (85.8%) patients had aggressive lymphoma. The frequency of bone marrow infiltration in our NHL patients was found to be 31.5%. Pattern of infiltrate was diffuse (14.6%) predominantly followed by interstitial (6.5%) and paratrabecular (5.4%) types of infiltration. The least common was nodular infiltrate accounted in 9 (4.8%) patients. CONCLUSIONS: B-cell lymphoma is more frequent than T-cell lymphoma. Younger age, aggressive lymphoma, and predominance of B-symptoms are more frequently seen. Diffuse bone marrow infiltration is more common in our set up probably because of a relatively late presentation in our patients.


Sign in / Sign up

Export Citation Format

Share Document